Fig. 6: LSC-Exo prevents the infection of SARS-CoV-2 D614G and B.1.617.2 (Delta) pseudoviruses.
From: Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2
a Flow cytometry of A549 cells infected with SARS-CoV-2 D614G pseudovirus, which were inhibited by LSC-Exo, HEK-Exo or rhACE2 treatment and the corresponding quantification analysis (b). n = 3. Gating strategy was shown in Fig. S20b. c Flow cytometry of SARS-CoV-2 B.1.617.2 (Delta) pseudovirus-infected A549 cells treated with LSC-Exo, HEK-Exo or rhACE2 and its corresponding quantification analysis (d). n = 3. Gating strategy was same with Fig. S20b. e Ex vivo IVIS imaging of infected lungs from mice with SARS-CoV-2 D614G or B.1.617.2 (Delta) pseudovirus challenge. rhACE2 or HEK-Exo or LSC-Exo was inhaled at 2 h before challenge. f Quantitative fluorescence intensity of SARS-CoV-2 D614G or B.1.617.2 (Delta) pseudoviruses from Fig. 6e. n = 3. Confocal images to show the distribution of SARS-CoV-2 D614G pseudovirus (g) and B.1.617.2 (Delta) pseudovirus (h) in whole lung tissues from the mice with LSC-Exo or HEK-Exo or rhACE2 treatment. Scale bar: 100 μm. Quantitative of pseudoviruses positive signals in both trachea/bronchioles and parenchyma from mice challenged with D614G (i) or B.1.617.2 (Delta) (j) pseudovirus. n = 10 images from 5 hamsters. k Cytokine array to determine inflammatory cytokines from mice serum 7 days after LSC-Exo inhalation. Data are mean ± s.d. One-way ANOVA with Bonferroni correction was performed for statistical analysis. Source data are provided as a Source Data file.
